Monitor upcoming clinical trial enrollment updates and any further FDA guidance on the 505(b)(2) pathway for PF614-MPAR, as regulatory progress remains a key value driver despite limited financial scale.
Price Chart
Executive Summary
Ensysce Biosciences reported fourth quarter and full-year 2025 financial results, showing a narrower net loss of $2.8M vs $3.6M in the prior year quarter, driven by lower R&D expenses. The company highlighted clinical progress, including patient enrollment in its Phase 3 PF614 trial and FDA feedback supporting a streamlined 505(b)(2) pathway for PF614-MPAR. Cash increased to $4.3M following financing activities.
Key Financial Metrics
Key Facts
- Net loss attributable to common stockholders was $2.8M for Q4 2025, improved from $3.6M in Q4 2024.
- R&D expenses decreased to $3.6M in Q4 2025 from $3.8M in the prior year quarter.
- Cash and cash equivalents were $4.3M as of December 31, 2025, up from $3.5M at the end of 2024.
- Enrollment began in the pivotal Phase 3 PF614-301 trial for post-surgical pain in December 2025.
- FDA provided encouraging feedback on the development pathway for PF614-MPAR, supporting overdose-protection labeling and a potential 505(b)(2) regulatory pathway.
Financial Impact
Reduced quarterly net loss by $0.8M year-over-year with stable revenue-like grant funding of $1.9M.
Risk Factors
- Continued reliance on federal grants and future financings to fund operations.
- High cash burn relative to current cash balance, with $7.8M used in operating activities in 2025.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-013622 |
| Document: form8-k.htm | 0001493152-26-013622 |
| Document: 0001493152-26-013622-index-headers.html | 0001493152-26-013622 |
| Document: 0001493152-26-013622-index.html | 0001493152-26-013622 |
| Document: 0001493152-26-013622.txt | 0001493152-26-013622 |
| 8-K Data (Synthetic) | 0001493152-26-013622 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 4, 2026 20w ago | S-3 | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | 8-K | — | awaiting T+20 | — | — |
May 15, 2026 23w ago | 8-K | — | awaiting T+20 | — | — |
Apr 3, 2026 29w ago | 8-K | — | awaiting T+20 | — | — |
Mar 30, 2026 30w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers